Your browser doesn't support javascript.
loading
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Marignier, Romain; Pittock, Sean J; Paul, Friedemann; Kim, Ho Jin; Bennett, Jeffrey L; Weinshenker, Brian G; Wingerchuk, Dean M; Green, Ari J; Fujihara, Kazuo; Cutter, Gary; Aktas, Orhan; Hartung, Hans-Peter; Drappa, Jorn; Ratchford, John N; She, Dewei; Smith, Michael; Rees, William; Cimbora, Daniel; Katz, Eliezer; Cree, Bruce A C.
Afiliação
  • Marignier R; Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (MIRCEM), Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France. Electronic address: romain.marignier@
  • Pittock SJ; Mayo Clinic, Rochester, MN, United States.
  • Paul F; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Kim HJ; Research Institute and Hospital of National Cancer Center, Goyang, Republic of Korea.
  • Bennett JL; University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, United States.
  • Weinshenker BG; Mayo Clinic, Rochester, MN, United States.
  • Wingerchuk DM; Department of Neurology, Mayo Clinic, Scottsdale, AZ, United States.
  • Green AJ; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, United States; UCSF Weill Institute for Neurosciences, Department of Ophthalmology, University of California San Francisco, San Francisco, CA, United States.
  • Fujihara K; Department of Multiple Sclerosis Therapeutics, Fukushima Medical University; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern Tohoku Research Institute for Neuroscience, Koriyama, Japan.
  • Cutter G; University of Alabama at Birmingham, Birmingham, AL, United States.
  • Aktas O; Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Hartung HP; Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; Brain and Mind Center, University of Sydney, Sydney, Australia; Medical University Vienna, Vienna, Austria; Department of Neurology, Palacky University in Olomouc, Olomouc, Czech Republic.
  • Drappa J; Horizon Therapeutics, Gaithersburg, MD, United States.
  • Ratchford JN; Horizon Therapeutics, Gaithersburg, MD, United States.
  • She D; Horizon Therapeutics, Gaithersburg, MD, United States.
  • Smith M; Horizon Therapeutics, Gaithersburg, MD, United States.
  • Rees W; Horizon Therapeutics, Gaithersburg, MD, United States.
  • Cimbora D; Horizon Therapeutics, Gaithersburg, MD, United States.
  • Katz E; Horizon Therapeutics, Gaithersburg, MD, United States.
  • Cree BAC; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, United States.
Mult Scler Relat Disord ; 57: 103356, 2022 Jan.
Article em En | MEDLINE | ID: mdl-35158465
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neuromielite Óptica Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neuromielite Óptica Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article